Summit Therapeutics PLC ADR (SMMT)

Currency in USD
10.500
-0.170(-1.59%)
Closed·
10.690+0.190(+1.81%)
·
Advertisement
Trading near 52-week Low
SMMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.14011.389
52 wk Range
10.14029.230
Key Statistics
Prev. Close
10.5
Open
10.24
Day's Range
10.14-11.389
52 wk Range
10.14-29.23
Volume
12.1M
Average Volume (3m)
6.63M
1-Year Change
-36.5942%
Book Value / Share
0.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SMMT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.033
Upside
+176.50%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

11 Buy
5 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.033
(+176.50% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink
Hold---Maintain18/11/2026
Bernstein SocGen Group
Sell8.30-20.95%-Downgrade18/11/2026
Barclays
Hold18.00+71.43%20.00Maintain16/11/2026
Jefferies
Buy30.00+185.71%-Maintain15/11/2026
Stifel
Buy37.00+252.38%38.00Maintain05/11/2026

Summit Therapeutics PLC ADR Earnings Call Summary for Q2/2026

  • Summit posted Q2 loss of $0.37/share vs. $0.28 expected, a 32.6% miss; shares fell 4.6% after hours despite 1.6% regular-session gain.
  • Cash rose to $690.7M from $598.7M in Q1 via $231M ATM raise; operating expenses jumped 24% to $151.8M on three Phase III trials.
  • Updated HARMONi survival data showed 0.76 hazard ratio; company maintains Nov. 14, 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC.
  • Key milestones: HARMONi-3 squamous PFS data H2 2026, OS interim analysis H1 2027, Arcus collaboration data mid-2027.
  • Filed new $380M ATM facility for financing flexibility; commercial launch prep underway with leadership in place, field force hiring near approval.
Last Updated: 23/07/2026, 22:50
Read Full Transcript

Earnings

Latest Release
04/11/2026
EPS / Forecast
-0.27 / -0.29
Revenue / Forecast
-- / 71.43K
EPS Revisions
Last 90 days

Compare SMMT to Peers and Sector

Metrics to compare
SMMT
Peers
Sector
Relationship
P/E Ratio
−10.1x−2.6x−0.2x
PEG Ratio
−0.70−0.030.00
Price/Book
14.9x1.9x2.6x
Price / LTM Sales
-189.1x2.7x
Upside (Analyst Target)
175.7%142.0%69.6%
Fair Value Upside
Unlock4.2%11.7%Unlock

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
48.13M6.02%568.89M
Other Institutional Investors
118.42M14.81%1.40B
Public Companies & Retail Investors
633.22M79.18%7.48B
Total
799.76M100.00%9.45B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Baker Bros. Advisors LP4.10%32,786,348387,535
Akeso, Inc.4.01%32,057,147378,915

People Also Watch

146.21
SCCO
-5.93%
94.15
CBRS
-9.63%
76.33
APH
-0.04%
40.790
AAOI
-9.80%
47.83
CRWV
-4.13%

FAQ

What Is the Summit Therapeutics PLC ADR (NASDAQ: SMMT) Share Price Today?

The Summit Therapeutics PLC ADR stock price today is 10.500 USD.

What Stock Exchange Does Summit Therapeutics PLC ADR (SMMT) Trade On?

Summit Therapeutics PLC ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Summit Therapeutics PLC ADR?

The stock symbol (also called a 'ticker') for Summit Therapeutics PLC ADR is "SMMT."

What Is the Current Summit Therapeutics PLC ADR Market Capitalisation?

As of today, Summit Therapeutics PLC ADR (NASDAQ: SMMT) market cap is 8.400B USD.

What Is Summit Therapeutics PLC ADR's (SMMT) Earnings Per Share (TTM)?

The Summit Therapeutics PLC ADR EPS is currently -1.07 (Trailing Twelve Months).

When Is the Next Summit Therapeutics PLC ADR Earnings Date?

Summit Therapeutics PLC ADR's next earnings report will be released on 18/03/2027.

Is SMMT a Buy or Sell From a Technical Analyst Perspective?

Based on today's Summit Therapeutics PLC ADR moving averages and other technical indicators, the daily buy/sell signal for SMMT stock is Strong Sell.

How Many Times Has Summit Therapeutics PLC ADR Stock Split?

Summit Therapeutics PLC ADR has split 0 times. (See the SMMT stock split history page for full effective split date and price information.)

How Many Employees Does Summit Therapeutics PLC ADR Have?

Summit Therapeutics PLC ADR has 265 employees, based on their latest Companies House report.

What is the current trading status of Summit Therapeutics PLC ADR (NASDAQ: SMMT)?

As of 19/11/2026, Summit Therapeutics PLC ADR (SMMT) is trading at a share price of 10.500 USD, with a previous close of 10.500 USD. The stock has fluctuated within a day range of 10.140 USD to 11.389 USD, while its 52-week range spans from 10.140 USD to 29.230 USD.

What Is Summit Therapeutics PLC ADR (SMMT) Price Target According to Analysts?

The average 12-month price target for Summit Therapeutics PLC ADR is 29.033 USD, with a high estimate of 42.7150926 USD and a low estimate of 8.24773414 USD. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +176.50% Upside potential.

What Is the SMMT After Hours Price?

SMMT's last after hours stock price is 10.690 USD, the stock has decreased by 0.190, or 1.810%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.